| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_46e75c1add395acfd985b93fe4553865
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8a5ab2aef013ffd967904238e6f779f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f223fd81a50a52cd7d8328f186ea53d7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-191 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2004-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97e20e6221a56a7445d3ccbb07af309e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1185134768de35d93f98974c8e3e73ee |
| publicationDate |
2004-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004105733-A1 |
| titleOfInvention |
Method and composition for stable and controlled delivery of (-)-hydroxycitric acid |
| abstract |
The present invention provides stable encapsulated (-)-hydroxycitric acid ('HCA')containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1713454-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1713454-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8403344-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11066423-B2 |
| priorityDate |
2003-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |